quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

KNG’s 8.6 Percent Yield Comes From Selling Calls on Dividend Aristocrats, And It Has Lagged NOBL Since 2018

View original at finance.yahoo.com
KNG’s 8.6 Percent Yield Comes From Selling Calls on Dividend Aristocrats, And It Has Lagged NOBL Since 2018 Quick Read FT Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG) holds 69 Dividend Aristocrats including Johnson & Johnson (JNJ) and Procter & Gamble (PG), selling covered calls monthly to generate an 8.6%…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investors who treat KNG's monthly distribution as a yield trap are receiving current income rather than a genuine alternative to share sales

    60% confidence
  • KNG targets an additional 8% yield above the underlying through its monthly covered call overlay

    60% confidence
  • Amplify CWP Enhanced Dividend Income ETF returned 66% over five years by selectively writing calls rather than overwriting the entire portfolio

    60% confidence
  • KNG returned 93% on a total-return basis from April 2018 through May 2026, while NOBL returned 107% over the same window

    60% confidence
  • ProShares NOBL charges 0.35% in expenses versus KNG's 0.74%

    60% confidence
  • KNG distributes roughly 8.6% yield by selling monthly covered calls against its 69 Dividend Aristocrat holdings

    60% confidence
  • JNJ rallied 55% over the trailing year

    60% confidence
  • Procter & Gamble has more than a century of uninterrupted dividend payments

    60% confidence
  • KNG underperformed NOBL by roughly 1.75% annualized over eight years, which compounds meaningfully

    60% confidence
  • KNG's income arrived as promised but was funded out of capital appreciation the holder handed away

    60% confidence
  • Selling covered calls on quality compounders like JNJ caps the upside that justifies owning Dividend Aristocrats, turning capital appreciation into current income

    60% confidence
  • A $100,000 allocation split between KNG and NOBL at inception in April 2018 leaves the NOBL sleeve materially larger today, even after KNG paid bigger monthly checks throughout

    60% confidence
  • KNG functions as a bond substitute that turns slow-growing quality compounders into a yield vehicle

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com